Recombinant NKG2A (Monalizumab Biosimilar) 抗体
Quick Overview for Recombinant NKG2A (Monalizumab Biosimilar) 抗体 (ABIN7581587)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
-
-
Expression System
- CHO Cells
-
原理
- Anti-NKG2A / CD94 Reference Antibody (monalizumab)
-
序列
- QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYWMNWVRQA PGQGLEWMGR IDPYDSETHY AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARGG YDFDVGTLYW FFDVWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL GK,DIQMTQSPSS LSASVGDRVT ITCRASENIY SYLAWYQQKP GKAPKLLIYN AKTLAEGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQH HYGTPRTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
-
产品特性
- Anti-NKG2A / CD159a Reference Antibody (monalizumab) is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
纯度
- >95 %
-
亚型
- IgG4 S228P
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
说明
-
Therapeutic Agents by Target and Mechanism: NKG2A antagonist
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
浓度
- 1 mg/mL
-
缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
储存条件
- 4 °C,-80 °C
-
储存方法
- +4°C,-80°C
-
-
- NKG2A (Monalizumab Biosimilar)
-
物质类
- Biosimilar
-
分子量
- 145.5 kDa
-
UniProt
- P26715
抗原
-